The Ministry of Innovative Development held talks with representatives of the Institute of Microbiology of Chinese Academy of Sciences and Anhui Zhifei Longcom Biopharmaceutical on conducting clinical trials of a recombinant coronavirus vaccine.
The vaccine, developed by this company and currently undergoing clinical trials, is an engineering-genetic protein of coronavirus surface antigen and has a high degree of safety when compared with adenovirus and inactivated vaccine. The engineering-genetic protein in the damaged body will produce antibodies against the virus.
If all the stages of clinical trials are successfully completed, Uzbekistan may be among the first to receive this vaccine at an affordable cost.
Specialists of the Ministry of Innovative Development together with Chinese partners have discussed issues related to the organization of the vaccination process and preparation for its implementation. It is expected that clinical trials will be conducted on a voluntary basis among people aged 18 and older. Before starting vaccination, Chinese specialists will conduct trainings to explain the conditions of vaccination.
